Key result
Higher Lp-PLA2 mass is linked to ~28% higher incident PAD risk per SD.
Cohort (n=4,537)
Answers are grounded in this paper and cite their sources.
OBJECTIVE: Although prior studies report a relationship between elevated lipoprotein-associated phospholipase A2 (Lp-PLA2) and incident cardiovascular disease, the prospective association of Lp-PLA2 with incident peripheral arterial disease (PAD) has not been studied. We investigated the association between Lp-PLA2 mass and activity and the risk of developing clinical PAD and low ankle-brachial index (ABI). APPROACH AND RESULTS: Among Cardiovascular Health Study participants, a population-based cohort of 5888 adults aged ≥65 years enrolled in 1989 to 1990, Lp-PLA2 mass and activity were measured in 4537 individuals without baseline PAD. Clinical PAD, defined as leg artery revascularization or diagnosed claudication, was ascertained through 2011. Incident low ABI, defined as ABI <0.9 and decline of ≥0.15, was assessed among 3537 individuals who had an ABI >0.9 at baseline and a second ABI measurement 3 or 6 years later. Analyses were adjusted for demographics, cholesterol, smoking, comorbidities, and C-reactive protein. Each standard deviation increment in Lp-PLA2 mass (117 ng/mL) was associated with a higher risk of developing clinical PAD (hazard ratio 1.28; 95% confidence interval 1.13, 1.45) and incident low ABI (odds ratio 1.16; 95% confidence interval 1.00, 1.33). Results per standard deviation increment in Lp-PLA2 activity (13 nmol/min per mL) were similar for clinical PAD (hazard ratio 1.24; 95% confidence interval 1.07, 1.44) and low ABI (odds ratio 1.28; 95% confidence interval 1.09, 1.50). CONCLUSIONS: Higher Lp-PLA2 mass and activity were associated with development of both incident clinical PAD and low ABI. Future studies are needed to determine whether pharmacological inhibition of Lp-PLA2 reduces the incidence of PAD.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2016) conducted a cohort in Peripheral arterial disease (n=4,537). Lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity vs. Per standard deviation increment (117 ng/mL for mass; 13 nmol/min per mL for activity) was evaluated on Incident clinical peripheral arterial disease (leg artery revascularization or diagnosed claudication) (HR 1.28, 95% CI 1.13-1.45). Higher Lp-PLA2 mass and activity were associated with increased risk of incident clinical PAD in older adults.
Synapse has enriched 10 related papers. Consider them for comparative context: